1 / 110

Cutaneous Vascular Diseases

Cutaneous Vascular Diseases. Michael Hohnadel, DO 10/11/05. Cutaneous small-vessel vasculitis (leukocytoclastic vasculitis). Presentation: Palpable purpura ranging in size from a pinpoint to several centimeters Early on lesion may not be palpable

colin
Télécharger la présentation

Cutaneous Vascular Diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Cutaneous Vascular Diseases Michael Hohnadel, DO 10/11/05

  2. Cutaneous small-vessel vasculitis(leukocytoclastic vasculitis) • Presentation: Palpable purpura ranging in size from a pinpoint to several centimeters • Early on lesion may not be palpable • Papulonodular, vascular, bullous, pustular or ulcerated forms may develop • Predominate on the ankles and lower legs • dependent areas • Mild pruritis, fever, malaise, arthralgia and/or myalgia may occur. Renal, GI

  3. Cutaneous small-vessel vasculitis(leukocytoclastic vasculitis) • Course: • Typically resolve in 3 to 4 weeks with postinflammatory hyperpigmentation • May recur or become chronic. • Histology: Angiocentric segmental inflammation, endothelial cell swelling, fibrinoid necrosis of blood vessel walls and a cellular infiltrate composed of neutrophils showing fragmentation of nuclei.

  4. Cutaneous small-vessel vasculitis(leukocytoclastic vasculitis) • Etilology • Many forms of small-vessel vasculitis are felt to be caused by circulating immune complexes. These lodge in vessel walls and activate compliment • Infections - bacterial and viral, Drugs, autoimmune disease, lymphoproliferative disorders and solid tumors.

  5. Cutaneous small-vessel vasculitis(leukocytoclastic vasculitis) Workup: • CBC, strep throat culture or ASO titer, Hep B & C serologies and ANA are a reasonable initial screen.

  6. Cutaneous small-vessel vasculitis Treatment • Initial treatment should be nonaggressive • Rest and elevation of the legs • Analgesics, a good diet, and avoidance of trauma or cold • Any identified antigen or drug should be eliminated

  7. Cutaneous small-vessel vasculitis Treatment: • A variety of systemic treatments may be required for severe, intractable or recurrent disease • For disease limited to the skin NSAIDs, antihistamines, colchicine and dapsone. • Systemic corticosteroids for those with systemic manifestations or necrotic lesions • Immunosuppressive agents for rapidly progressive course and severe systemic involvement

  8. LCV

  9. LCV • A. classical purpuric papules & papules on lower leg • B. CSVV evolving to form confluent hemorrhagic plaque on posteroir ankle • C. lesions in various stages of evolution

  10. Subtypes of Small-Vessel Vasculitis

  11. Henoch-Schönlein Purpura(HSP) (anaphylactoid purpura) • Presentation: Characterized by intermittent purpura, arthralgia, abdominal pain, and renal disease • 40 % preceded by mild fever, headache, joint symptoms, and abdominal pain for up to 2 weeks • Typically purpura appears on the extensor surfaces of the extremities • Become hemorrhagic within a day and fades in 5 days • New crops appear over a few weeks

  12. Henoch-Schönlein purpura • Primarily occurs in male children • Peak age 4-8 years • Adults may be affected. • Etiology: Viral infection or streptococcal pharyngitis are the usual triggering event. • May be related to a medications. • Complications: • Pulmonary hemorrhage, Abdominal pain and GI bleeding. • Renal manifestations may occur in 25% or more • Hematuria • Good Prognosis but should be monitored long term for IgA nephropathy

  13. Henoch-Schönlein purpura Treatment : • Supportive • Duration of illness is typically 6 to 16 weeks • 5 and 10 % of patients will have persistent or recurrent disease • Antispasmodics, antibiotics, and antiinflammatory drugs, including systemic corticosteroids • Plamaphoresis in severe cases

  14. Henoch - Schönlein purpura

  15. Henoch-Schönlein purpura

  16. Henoch-Schönlein purpura

  17. Acute Hemorrhagic edema of infancy • Presentation: • Child under the age of 2 with a recent history of an upper respiratory illness (75%) , a course of antibiotics of both. • Abrupt onset of large cockade, annular, or targetoid purpuric lesions involving the face, ears, and extremities • Early in the course there may first be acral edema, may be nontender and asymmetrical • Low-grade fever is common. • No extracutaneous involvement. Children are often nontoxic in appearance.

  18. Acute Hemorrhagic edema of infancy • Etiology: Considered a variant of leukocytoclastic vasculitis with many similarities to HSP • Routine lab tests are nondiagnostic • DDX: meningococcemia, HSP, erythema multiforme, urticaria and Kawasaki’s disease • Clinically most urgent to exclude meningococcemia • Course: Spontaneously resolves with 1-3 weeks

  19. Acute Hemorrhagic edema of infancy • Multiple erythematous, nummular & targetoid plaques on an infant’s thighs

  20. Urticarial vasculitis • Three clinical features distinguish the skin lesions of urticarial vasculitis from urticaria • Lesion are usually painful rather than pruritic • Lesions last longer than 24 hours • On healing there is postinflammatory hyperpigmentation • Systemic symptoms. • Assoc with hypocomplementemia (in some cases), arthritis, angioedemia, abdominal/chest pain.

  21. Urticarial vasculitis • Several erythematous urticarial plaques on the foot & ankle

  22. Urticarial vasculitis • Many disease associations: gammopathies, SLE, viral (hepatitis, EBV). • Treatment: • Pts with hypocomplementemic type respond to oral corticosteroids • Hydroxychloroquine sulfate, colchicine, dapsone, NSAIDs or pentoxifylline • Some pts require a combination of therapies with antihistamines

  23. Familial Mediterranean fever • A periodic fever syndrome reported to affect Sephardic Jews, Armenians, and individuals of Arabian descent. • Presentation: Cutaneous findings consist of erysipelas-like erythema showing a sharp border. • Erysipelas-like erythema occurs in less than half of patients • Affects the lower extremities on the dorsa of the feet , over the ankles, and sometimes the knees • Arthralgias, peritonitis, and constipation may occur • No lymphadenopathy

  24. Familial Mediterranean fever • Onset: Usually under 10 years • Biopsy: leukocytoclastic vasculitis • Tx - colchicine

  25. Erythema elevatum diutinum • A rare condition considered to be a chronic fibrosing leukocytoclastic vasculitis • Presentation: Multiple yellow papules develop over the joints, particularly the elbows, knees, hands, and feet • Initially nodules are soft & mobile then take on a doughy to firm consistency and develop red to purple. • Face & ears usually affected • Lesions may be painful or asymptomatic • Course: Variable, lasting 5-35 yrs. • Assoc: HIV. Gammopathies. • TOC: Dapsone

  26. Top: multiple symmetric red-brown nodules & plaques on extensor surface of digits • Bottom: red-brown palques & nodules of concha, antihelix & of the ear

  27. Erythema elevatum diutinum • Early stage: dense perivascular infiltrate of neutrophils admixed with lymphs & histiocytes • Late-stage: minimal inflammatory infiltrate & marked perivascular fibrous thickening

  28. Granuloma Faciale • Presentation: Brownish-red, infiltrated papules, plaques, and nodules typically on the face esp nose. (head or neck) • Typically healthy, middle aged, white men • Pathology: Identical to EED. Mixed vasculitis with less prominent fibrosis. • Treatment • Often resistant to TX. • Intralesional corticosteroids (first line non-scarring option) • Also: Cryotherapy, dermabrasion, electrosurgery, many others.

  29. Granuloma faciale Note prominent follicular openings

  30. Granuloma faciale • Left: dense, diffuse dermal infiltrate with a Grenz zone • Right: high power of polymorphous infiltrate of lymphocytes, eos, neuts & plasma cells

  31. Polyarteritis Nodosa • Characterized by necrotizing vasculitis affecting the small and medium-sized muscular arteries • Two major forms: • Systemic • Microscopic polyangiitis • Benign cutaneous

  32. Polyarteritis nodosa Systemic PAN • Cutaneous findings (40 %) • 15% of pts have 5 - 10 mm subcutaneous nodules occurring singly or in groups distributed along the course of blood vessels. • Skin above is normal or slightly erythematous • Often painful, may pulsate or ulcerate

  33. PAN • Top: petechiae & multiple purpuric papules with central necrosis on plantar surface • Bottom: confluent hemorrhagic plaques on the medial & plantar aspect of the foot

  34. Polyarteritis nodosa Systemic PAN • Internal manifestations: • May involve the vessels throughout the entire body. • Hypertension, tachycardia, fever, edema glomerulosclerosis and weight loss are the cardinal signs of the disease • Mononeuritis multiplex, most often manifested as foot drop, is the hallmark of PAN

  35. Polyarteritis nodosa Systemic PAN Laboratory findings: • Leukocytosis as high as 40,000 may occur with neutrophilia to 80% • Thrombocytosis and progressive normocytic anemia, elevated sed rate. • Urinary abnormalities seen in 70% • May have elevated C-ANCA (consult Dr. Berrett)

  36. Polyarteritis nodosa Microscopic Polyangiitis • Considered by many to be a subset of systemic PAN. • May be related to Wegner’s and Churg- Strauss. • Segmental, necrotizing and crescentic glomerulonephritis associated with extrarenal vasculitis involving small-size vessels without granulomas or asthma • Positive P-ANCA

  37. Polyarteritis nodosaepidemiology Systemic PAN • 4 X more common in men than women. Mean age 45 yrs. • Assoc with: IV drug abusers, SLE, inflammatory bowel disease, hairy cell leukemia, and familial Mediterranean fever. Also: Hep-B and Hep-C. (check ck for during work-up)

  38. Polyarteritis nodosa Systemic PAN • Histology: An inflammatory necrotizing and obliterative panarteritis that attacks the small and medium-sized arteries. • Biopsy is mainstay of diagnosis.

  39. Polyarteritis nodosa Systemic PAN Course: • Untreated classic PAN has a 5 year survival rate of 13%. • Death from renal failure, cardiovascular or GI complications Treatment: • High-dose corticosteroids with slow taper to DC. • Cytotoxic agents such as may be added like cyclophosphamide with taper to DC.

  40. Polyarteritis nodosa Cutaneous PAN • Absence of visceral involvement • Presentation: Recurrent skin, joint, and muscle involvement without involvement of vital organs • Cutaneous findings similar to those described for the systemic form • Assoc: Hep B,C. Crohn’s & others. • Most patient respond well to aspirin, prednisone, methotrexate, alone or in combination

  41. Wegener’s Granulomatosis • Syndrome consisting of: • Necrotizing granulomas of the upper and lower respiratory tract. • Generalized necrotizing angiitis affecting the medium-sized blood vessels. • Focal necrotizing glomerulitis.

  42. Wegener’s granulomatosis • Presentation: Rhinorrhea, severe sinusitis, and nasal mucosa ulcerations. One or several nodules in the nose, larynx, trachea, or bronchi. • Fever, weight loss and malaise • m:f = 1.3 : 1 Age 40 to 50 years. • “strawberry gums” = hypertrophic gingivitis • Focal necrotizing glomerulitis occurs in 85% of patients • Cutaneous findings (45% of patients) • Nodules may appear in crops, especially along the extensor surface of the extremities • Firm,slightly tender, flesh-colored or violaceous nodules may later ulcerate

  43. Wegener’s granulomatosis • LAB: (+) C – ANCA • Histology: Cutaneous lesions may demonstrate a leukocytoclastic vasculitis with or without granulomatous inflammation.

  44. Wegener’s granulomatosis Nodules on extensor surfaces

  45. Wegener’s granulomatosis • Left: purpuric plaques on the distal fingers • Right: ulceration of the tongue

  46. Wegener’s granulomatosis Prognosis and treatment: • Untreated the mean survival time is 5 months and a 90% mortality over 2 years. • Improves when corticosteroids are combined with cytotoxic drugs: • 75% remission rate, 87% survivalrate in pts between 6 months & 24 yrs

  47. Churg-Strauss Syndrome Presentation: • 3 clinical phases occur: • Prodrome: asthma, allergic rhinitis, peripheral blood eosinoiphilis & eosinophilic infiltrative dx • 2 – 12 years of prodrome. • Vasculitis, characterized by arthritis, & myositis with cardiac, pulmonary, nervous system, GI, renal, ocular or genitourinary dx. • Post-vasculitic phase-dominated by allergic rhinitis, asthma, HTN & peripheral nerve damage

  48. Churg-Strauss Syndrome • Cutaneous lesions • Most common features of the vasculitic phase (70%) • Most common skin findings are purpura & infiltrated nodules on extensor surfaces. • Less common are: necrotizing livedo reticularis, migratory erythema, new onset Raynaud’s phenomenon & digital ischemia. • Extracutaneous manifestations: wt loss, myalgias, arthralgias, mononeuritis multiplwex, GI symptoms, & cardiomyopathy

  49. Churg-Strauss Syndrome • Lab • Peripheral eosinophilia and (+) P-ANCA (less frequently for C-ANCA) • Correlate with disease severity • Histopathology: Sm. vessel vasculitis with eosinophils. • Etiology: Several drugs have been implicated: Zafirlukast, Azithromycin, freebase cocaine. • TX: prednisone alone clinical remission in >90% of pts

  50. Churg-Strauss Syndrome • Crusted, firm papules of the elbow

More Related